THERAVET SA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.682 EUR | 0.00% |
|
-3.40% | -52.97% |
| May. 07 | FOMO is Back |  |
| Apr. 23 | TheraVet SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2021 | 1.94M 2.11M | Sales 2022 | 1.6M 1.74M | Capitalization | 8.06M 8.75M |
|---|---|---|---|---|---|
| Net income 2021 | -1M -1.09M | Net income 2022 | -2M -2.17M | EV / Sales 2021 | 7.08 x |
| Net cash position 2021 | 4.63M 5.03M | Net cash position 2022 | 2.14M 2.32M | EV / Sales 2022 | 3.7 x |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
-3.48
x | Employees | 8 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -3.40% | ||
| Current month | -2.01% | ||
| 1 month | -12.56% | ||
| 3 months | -37.43% | ||
| 6 months | -63.92% | ||
| Current year | -52.97% |
1 week
0.64
0.71
1 month
0.640.79
Current year
0.641.46
1 year
0.642.40
3 years
0.648.56
5 years
0.648.56
10 years
0.648.56
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | - | 17-11-20 | |
Rodolphe Lebrun
DFI | Director of Finance/CFO | - | 23-10-23 |
Celine Molle
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | - | 17-11-20 | |
Simon Wheeler
CHM | Chairman | - | 21-12-19 |
Nesya Goris
BRD | Director/Board Member | - | 21-12-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 0.682 | 0.00% | 22 |
| 24-05-16 | 0.682 | +0.29% | 4,675 |
| 24-05-15 | 0.68 | -0.58% | 1,265 |
| 24-05-14 | 0.684 | 0.00% | 5,147 |
| 24-05-13 | 0.684 | -3.12% | 1,969 |
Real-time Euronext Paris, May 17, 2024 at 03:35 am EDT
More quotes
TheraVet SA is specialized in the development of pharmaceutical products for the treatment of osteoarticular diseases in pets.
At the end of 2023, the company had a portfolio of 2 products in the clinical development phase: Visco-Vet for the treatment of limping associated with osteoarthritis in dogs and Biocera-Vet for osseointegration and bone remodeling.
Calendar
2024-06-06
- Shareholders Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -52.97% | 2.39M | |
| +8.29% | 114B | |
| +10.21% | 104B | |
| +0.23% | 22.28B | |
| -11.90% | 22.41B | |
| -4.78% | 19.07B | |
| -37.36% | 18B | |
| -5.17% | 17.89B | |
| +7.70% | 14.28B | |
| +37.65% | 12.55B |
- Stock Market
- Equities
- ALVET Stock
